Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Pressure Biosciences' technology is building momentum

Revenues are on the rise and the group’s efforts to bring in new business is delivering.
The group has a valuable new tool for research

Pressure Biosciences Inc (OTCMKTS:BIO) has seen momentum building behind its proprietary technology  and it is primed for a successful fiscal 2017.

Revenues are on the rise and the group’s efforts to bring in new business is delivering.

The firm develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6bn sample preparation market.

The company got a major shot in the arm in December and now sees itself playing a key role in a new cancer research initiative in the United States, following the introduction of new legislation.

First quarter shows financial and operational success

Sales of products and services helped boost revenues in the first quarter. Total revenue came in at $551,357 for the three months to March 31, compared to $510,478 during the same period of 2016, despite the decrease in grant revenue.

Products and services revenue increased 16% to $525,998, mainly due to a 19% increase in instrument systems sales.

Sales of consumables also increased 43% to $63,264 in the quarter.

The operating loss decreased 4% to $999,103 from $1,045,945 for the same quarter of 2016.

A CE mark for preparation instrument

In February this year, it achieved a CE Marking for its sample preparation instrument  Barocycler 2320EXTREME, giving it the green light to sell the product in Europe.

It can now market and sell the device in all 31 countries in the European Economic Area.

Meanwhile, in March, it significantly bolstered its sales capabilities by contracting with lead generating firm EKG Sales Associates, and by hiring two of its planned four field sales directors.

And it has now welcomed back veteran financial executive Joseph L Damasio back to the company, appointing him vice-president of finance and chief financial officer.

Damasio was employed at Pressure in 2007 as accounting manager, then as controller a year later and as vice president of finance and administration in 2011.

A major role in a cancer moonshot

In December, 2016, the company told investors that it expects to play a key role in the US $1.8bn “Cancer Moonshot” initiative after legislation was signed.

Specifically, it is set to benefit from the 21st Century Cures Act which included $1.8bn earmarked specifically for cancer research.

Pressure BioSciences’ technology is already being featured as an essential technology and used by leading researchers participating in the ‘Cancer Moonshot’ and other important research programs.

This program aims to accelerate cancer research and support other avenues that will improve the ability to understand, prevent, detect, treat, and even cure cancer. Its goal is to try and achieve in the next five years what would normally take ten years to complete.

This will be achieved in part by increasing the number of cancer researchers and studies, increasing the sharing of samples and data among these researchers, and by offering cancer researchers access to 21st Century, cutting-edge laboratory tools (instruments, consumables, etc.) that will enhance and improve their research studies.

Proprietary technology and winning over opinion leaders

Pressure Biosciences’ proprietary PCT-HD system has in recent years been trialled and adopted by leading scientists.

“We have a unique, patented technology that is now beginning to be appreciated by scientists around the world,” Richard Schumacher, the group’s founder and chief executive said earlier this year.

Schumacher highlighted that generally the life sciences have moved on significantly in past decades with the focus increasingly upon the intricacies within cells rather than what occurs around the outsides of them.

However, he says the technological approach to actually ‘open’ cells remains relatively crude and are still largely the same as they were in the 1980s (when he was last in the lab in a scientific capacity).

At Pressure BioSciences we’ve developed this new method, never been used before, to open the cell and get “all the good stuff” out.

“Essentially it is like a sponge, we squeeze it out. Where others beat up ‘the sponge’ using mechanical, we put it in a pressure chamber. It is much gentler, it is much more controllable.”

Schumacher points out that, generally speaking, scientists are stubborn people by nature,  and convincing them to change their working practices has been one of the biggest challenges for the company.

But, by targeting what he calls ‘key opinion leaders’ in certain specialist fields Schumacher says Pressure Bioscience has started to overcome this hurdle.

“You have to go after the key opinion leaders. The scientists around the world that are recognised as the experts in studying proteins, DNA, RNA and lipids.

“We have to go after them and get them to use the technology with the assumption that once they’ve used it, they’ll realise how much better the system is. That’s what we’ve done."

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use